1. Volume 84, Issue 5, Pages 998-1008 (November 2013)
Use of phosphate-binding agents is associated with a lower risk of mortality 
Jorge B. Cannata-Andía, José L. Fernández-Martín, Francesco Locatelli, Gérard London, José L. Gorriz, Jürgen Floege, Markus Ketteler, Aníbal Ferreira, Adrian Covic, Boleslaw Rutkowski, Dimitrios Memmos, Willem-Jan Bos, Vladimir Teplan, Judit Nagy, Christian Tielemans, Dierik Verbeelen, David Goldsmith, Reinhard Kramar, Pierre-Yves Martin, Rudolf P. Wüthrich, Drasko Pavlovic, Miha Benedik, José Emilio Sánchez, Pablo Martínez-Camblor, Manuel Naves-Díaz, Juan J. Carrero, Carmine Zoccali 
Kidney International 
Volume 84, Issue 5, Pages (November 2013)
DOI: /ki
Copyright © 2013 International Society of Nephrology Terms and Conditions

2. Figure 1
Hazard ratios of unadjusted relative all-cause and cardiovascular mortality in different subgroups of patients prescribed or not prescribed phosphate-binding agents (PBAs). CV, cardiovascular; CVD, cardiovascular disease.
Kidney International  , DOI: ( /ki )
Copyright © 2013 International Society of Nephrology Terms and Conditions

3. Figure 2
Relative all-cause and cardiovascular mortality in patients prescribed different types of phosphate-binding agents (PBAs). Unadjusted (univariate) and after adjustments with the three multivariate models used. HR, hazard ratio.
Kidney International  , DOI: ( /ki )
Copyright © 2013 International Society of Nephrology Terms and Conditions

4. Figure 3
Relative all-cause mortality in patients prescribed the most currently used phosphate-binding agents (PBAs) excluding those labeled as ‘others’. Unadjusted (univariate) and after adjustments with the three multivariate models used. CI, confidence interval; HR, hazard ratio.
Kidney International  , DOI: ( /ki )
Copyright © 2013 International Society of Nephrology Terms and Conditions